Today: 9 April 2026
XRP stock slides as Senate delays key crypto bill vote; what traders watch next
15 January 2026
1 min read

XRP stock slides as Senate delays key crypto bill vote; what traders watch next

New York, Jan 15, 2026, 13:11 EST — Regular session

  • XRP stock (Bitwise XRP ETF) dropped roughly 3% around midday following the delay of a Senate crypto-bill session
  • The delay also impacted other crypto-related stocks, including Coinbase
  • Traders are focused on when the bill talks will resume and the Senate’s schedule for next week

Shares of the Bitwise XRP ETF—popularly called “XRP stock” among retail investors—dropped 3.2%, slipping to $23.37 in Thursday afternoon trading. The decline followed the U.S. Senate Banking Committee’s decision to delay a key session on a major crypto market-structure bill. Senate Banking Committee

The bill is significant because it aims to clarify which U.S. regulator is responsible for what in crypto markets—a shift investors see as a possible gateway to more institutional interest. When it comes to XRP-related products, the idea of having “rules you can trade around” has come up repeatedly this year. Congress.gov

In the underlying market, XRP — the token — dropped roughly 2.7% in the last 24 hours, trading near $2.08. This kind of move usually filters through swiftly to spot-based funds. CoinMarketCap

Crypto-linked stocks took a hit as Washington’s delay weighed on the sector. Coinbase Global dropped roughly 3.3%. According to a Barron’s report, Coinbase withdrew its support for the bill, pointing to concerns over restrictions on stablecoin rewards and new limits affecting tokenized equities and decentralized finance.

The pullback came following a short rally in digital assets earlier this week, driven by traders betting that lawmakers were edging toward a viable regulatory framework. Barron’s

SEC Chairman Paul Atkins labeled this week as “a big week for crypto” in a post on X and pushed for movement on bipartisan market-structure legislation. X (formerly Twitter)

Not everyone is sold on speed. Lynn Turner, former SEC chief accountant, called the draft “severely deficient” in investor protections in a letter, warning it might open the door to “another FTX-type fraud,” according to a Thomson Reuters Checkpoint News report. Thomson Reuters Tax

Other U.S.-listed XRP funds also slipped in sympathy. The Canary XRP ETF dropped roughly 2.8%, Franklin’s XRP fund lost around 3.2%, Grayscale’s XRP vehicle edged down about 2.8%, and the REX-Osprey XRP ETF fell close to 2.9%.

The Bitwise XRP ETF started trading on NYSE Arca in November, offering investors a way to gain exposure to XRP without owning the token itself. Bitwise Investments

The downside is clear: should the bill’s compromise collapse—especially over stablecoin yields and DeFi regulation—the legislative timeline could drag out, and the “regulatory clarity” trade might unravel quickly. The committee has pushed back against criticism in its own releases, but the concerns persist. Senate Banking Committee

Traders are now waiting for fresh timing from the Banking Committee, alongside the Senate Agriculture Committee’s scheduled release of its crypto package on Jan. 21. This move could shift expectations once more. Investors.com

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:12 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Morgan Stanley stock jumps nearly 6% after earnings beat and dividend lift
Previous Story

Morgan Stanley stock jumps nearly 6% after earnings beat and dividend lift

Gold price today: GLD stock slips as dollar firms on jobless-claims surprise, Fed in view
Next Story

Gold price today: GLD stock slips as dollar firms on jobless-claims surprise, Fed in view

Go toTop